Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: Ms. X who wrote (1932)	3/23/1998 11:01:00 AM
From: Jerry Olson	Respond to of 34811

Janie Hey put me on that list too<g>> I can't begin to tell you & Tom, how much i have profited from P&F...it's been a real trip for me... of course with this excellent thread and your backup i feel very confident of making large amounts of $$$$$$$$$ this year... Both of you keep up the great work... My Regards, Jerry

To: Ms. X who wrote (1932)	3/23/1998 3:21:00 PM
From: Ms. X	Respond to of 34811

(DJ) Technical Analyst sees Pfizer shares at $120 on New Drug New York (Dow Jones) Pfizer Inc.'s new impotence drug could boost its stock price to more than 120, Tom Dorsey, partner and technical analyst with Dorsey Wright & Associates, said during an appearance on CNBC Friday... Pfizer plans to put its new impotence pill on the market during the second quarter, pending food and drug administration approval, a company spokesman said. Last year the FDA put the drug, known as Viagra, on fast-track review, committing itself to act on the application within six months. That time-frame ends at the end of this month. In addition to Pfizer, Dorsey named Chevron Corp. and Mcdonalds.